The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aside from trial-specific information, publication of data to publicly accessible databases is at the discretion of the trial leads and in many cases is not available85.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [85]
In the citing paper
“Further, the vast majority of trials utilizing pluripotent stem cells involve in vitro disease modeling.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [85]
In the citing paper
“In cases where public disclosure is provided, details are scarce.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [85]
In the citing paper
“A lack of public disclosure in the majority of clinical trials is evident, with very few trials citing publications with reference to pre-clinical work, bioprocess strategies, characterization specifics, manufacturing details, or other pipeline information.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [85]
In the citing paper
“As of August 2021, only 1.2% of documented stem-cell-derived therapeutic clinical trials in the United States alone utilized iPSCs.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [85]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schwartz, S. D., Regillo, C. D., Lam, B. L., Eliott, D., Rosenfeld, P. J., Gregori, N. Z., Hubschman, J.-P., Davis, J. L., Heilwell, G., Spirn, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61376-3 · Cited by 1,327
Song, W. K., Park, K.-M., Kim, H.-J., Lee, J. H., Choi, J., Chong, S. Y., Shim, S. H., Del Priore, L. V., & Lanza, R. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.005 · Cited by 393
A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem Cells
Kurtz, A., Seltmann, S., Bairoch, A., Bittner, M.-S., Bruce, K., Capes-Davis, A., Clarke, L., Crook, J. M., Daheron, L., Dewender, J., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.002 · Cited by 47
Self-citation
Research works printed but not linked: 31
- Alper, 2009, Geron gets green light for human trial of ES cell-derived product, Nat. Biotechnol., 27, 213, 10.1038/nbt0309-213a · DOI · Paper page
- Amit, 2002, Derivation and spontaneous differentiation of human embryonic stem cells, J. Anat., 200, 225
- D'Amour, 2006, Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells, Nat. Biotechnol., 24, 1392, 10.1038/nbt1259 · DOI · Paper page
- Desgres, 2019, Clinical translation of pluripotent stem cell therapies: challenges and considerations, Cell Stem Cell, 25, 594, 10.1016/j.stem.2019.10.001 · DOI
- Draper, 2004, Culture and characterization of human embryonic stem cells, Stem Cell Dev., 13, 325, 10.1089/scd.2004.13.325 · doi:10.1089/scd.2004.13.325 · Paper page
- Guhr, 2018, Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials, Stem Cell Reports, 11, 485, 10.1016/j.stemcr.2018.06.012 · DOI
- Guhr, 2006, Current state of human embryonic stem cell research: an overview of cell lines and their use in experimental work, Stem Cells, 24, 2187, 10.1634/stemcells.2006-0053 · DOI
- Isasi, 2019, A pathway for attesting ethical provenance of cell lines: lessons from the European Human Pluripotent Stem Cell Registry (hPSC(reg)), Stem Cell Res., 40, 101539, 10.1016/j.scr.2019.101539 · DOI
- Kaupisch, 2012, Derivation of vascular endothelial cells from human embryonic stem cells under GMP-compliant conditions: towards clinical studies in ischaemic disease, J. Cardiovasc. Transl. Res., 5, 605, 10.1007/s12265-012-9379-2 · doi:10.1007/s12265-012-9379-2
- Kobold, 2015, Human embryonic and induced pluripotent stem cell research trends: complementation and diversification of the field, Stem Cell Reports, 4, 914, 10.1016/j.stemcr.2015.03.002 · DOI
- Li, 2014, The global landscape of stem cell clinical trials, Regen. Med., 9, 27, 10.2217/rme.13.80 · DOI
- Liu, 2018, Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration, Cell Discov., 4, 50, 10.1038/s41421-018-0053-y · DOI
- Löser, 2012, Scope and impact of international research in human pluripotent stem cells, Stem Cell Rev. Rep., 8, 1048, 10.1007/s12015-012-9409-0 · DOI
- Löser, 2010, Human embryonic stem cell lines and their use in international research, Stem Cells, 28, 240, 10.1002/stem.286 · DOI
- Lund, 2006, Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats, Cloning Stem Cells, 8, 189, 10.1089/clo.2006.8.189 · DOI · Paper page
- Mandai, 2017, Autologous induced stem-cell-derived retinal cells for macular degeneration, N. Engl. J. Med., 376, 1038, 10.1056/NEJMoa1608368 · DOI · Paper page
- Menasche, 2018, Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction, J. Am. Coll. Cardiol., 71, 429, 10.1016/j.jacc.2017.11.047 · DOI · Paper page
- Parmar, 2020, The future of stem cell therapies for Parkinson disease, Nat. Rev. Neurosci., 21, 103, 10.1038/s41583-019-0257-7 · DOI · Paper page
- Schulz, 2015, Concise review: manufacturing of pancreatic endoderm cells for clinical trials in type 1 diabetes, Stem Cell Transl. Med., 4, 927, 10.5966/sctm.2015-0058 · DOI
- Schwartz, 2012, Embryonic stem cell trials for macular degeneration: a preliminary report, Lancet, 379, 713, 10.1016/S0140-6736(12)60028-2 · DOI · Paper page
- Seltmann, 2016, hPSCreg—the human pluripotent stem cell registry, Nucleic Acids Res., 44, D757, 10.1093/nar/gkv963 · DOI
- Senior, 2019, Stem cell therapies for Type 1 diabetes: current status and proposed road map to guide successful clinical trials, Diabetic Med., 36, 297, 10.1111/dme.13846 · DOI
- Silvestro, 2020, Stem cells therapy for spinal cord injury: an overview of clinical trials, Int. J. Mol. Sci., 21, 10.3390/ijms21020659 · DOI
- Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Tannenbaum, 2012, Derivation of xeno-free and GMP-grade human embryonic stem cells--platforms for future clinical applications, PLoS One, 7, e35325, 10.1371/journal.pone.0035325 · DOI
- Thomson, 1998, Embryonic stem cell lines derived from human blastocysts, Science, 282, 1145, 10.1126/science.282.5391.1145 · DOI · Paper page
- Trounson, 2001, Human embryonic stem cells, Fertil. Steril., 76, 660, 10.1016/S0015-0282(01)02880-1 · DOI
- Vitillo, 2020, Treatment of age-related macular degeneration with pluripotent stem cell-derived retinal pigment epithelium, Curr. Eye Res., 45, 361, 10.1080/02713683.2019.1691237 · DOI
- Wattanapanitch, 2019, Recent updates on induced pluripotent stem cells in hematological disorders, Stem Cell Int., 2019, 5171032
- Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science, 318, 1917, 10.1126/science.1151526 · DOI · Paper page
- Zarbin, 2019, Concise review: update on retinal pigment epithelium transplantation for age-related macular degeneration, Stem Cell Transl. Med., 8, 466, 10.1002/sctm.18-0282 · DOI
Cited by
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00183-7 · Cited by 33
Genetic Engineering of Immune Evasive Stem Cell-Derived Islets
Sackett, S. D., Kaplan, S. J., Mitchell, S. A., Brown, M. E., Burrack, A. L., Grey, S., Huangfu, D., & Odorico, J. (2022) · Transplant International · doi:10.3389/ti.2022.10817 · Cited by 32
Metadata
- Authors
- Kobold, S., Guhr, A., Mah, N., Bultjer, N., Seltmann, S., Seiler Wulczyn, A. E. M., Stacey, G., Jie, H., Liu, W., Löser, P., & Kurtz, A.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 15
- Issue
- 2
- Pages
- 546-555
- ISSN
- 2213-6711
- Cited by
- 66
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- European Commission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells. https://app.cochat.ai/papers/10.1016/j.stemcr.2020.06.014
- The paper
- Kobold, S., Guhr, A., Mah, N., Bultjer, N., Seltmann, S., Seiler Wulczyn, A. E. M., Stacey, G., Jie, H., Liu, W., Löser, P., & Kurtz, A. (2020). A Manually Curated Database on Clinical Studies Involving Cell Products Derived from Human Pluripotent Stem Cells. Stem Cell Reports. https://doi.org/10.1016/j.stemcr.2020.06.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.